Assessing Patient Eligibility for CAR-T Therapy
Opinion
Video
This segment explores factors influencing patient candidacy for CAR-T therapy, including age, fitness, and relapse specifics, and evaluates key findings from the KarMMa trials to compare ide-cel with other second-line treatment options for multiple myeloma.
Video content above is prompted by the following:
- What factors make Rosie a strong candidate for CAR-T therapy?
- How do considerations like her age, overall fitness, and specifics of her relapse shape your decision?
- Are there other treatment paths you would explore for this patient?
- Let’s examine the data backing the use of ide-cel in this context:
- Which major findings from the KarMMa and KarMMa-3 trials are most relevant to your decision-making?
- How do these outcomes compare with other second-line options available for multiple myeloma?
Recent Videos
Related Content
Considering NCCN Guidelines to Determine Maintenance Therapy Multiple Myeloma
February 15th 2025Article
During the 66th American Society of Hematology Annual Meeting and Exposition, experts in multiple myeloma gathered to discuss the impact of maintenance therapy and minimal residual disease (MRD) in patients with newly diagnosed transplant-eligible or -ineligible multiple myeloma.
